Stifel analyst Mathew Blackman raised the firm’s price target on DexCom to $100 from $90 and keeps a Buy rating on the shares. Stifel noted that DexCom shares are down 34.8% since Q2, and while the firm made downward discounted cash flow revisions to reflect updated guidance with a more conservative second half, the discounted cash flow still “suggests $132/share value.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before October 21, 2024 to Discuss Your Rights – DXCM
- Street analysts say diabetes stocks âoverreactingâ to Lilly GLP-1 study results
- Diabetes stock selloff on Lilly Surmount-1 results overdone, says Citi
- QQQ ETF Update, 8/21/2024
- DexCom price target lowered to $130 from $145 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com